Contribution of FKBP5 Genetic Variation to Gemcitabine Treatment and Survival in Pancreatic Adenocarcinoma
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
PURPOSE: FKBP51, (FKBP5), is a negative regulator of Akt. Variability in FKBP5 expression level is a major factor contributing to variation in response to chemotherapeutic agents including gemcitabine, a first line treatment for pancreatic cancer. Genetic variation in FKBP5 could influence its function and, ultimately, treatment response of pancreatic cancer. EXPERIMENTAL DESIGN: We set out to comprehensively study the role of genetic variation in FKBP5 identified by Next Generation DNA resequencing on response to gemcitabine treatment of pancreatic cancer by utilizing both tumor and germline DNA samples from 43 pancreatic cancer patients, including 19 paired normal-tumor samples. Next, genotype-phenotype association studies were performed with overall survival as well as with FKBP5 gene expression in tumor using the same samples in which resequencing had been performed, followed by functional genomics studies. RESULTS: In-depth resequencing identified 404 FKBP5 single nucleotide polymorphisms (SNPs) in normal and tumor DNA. SNPs with the strongest associations with survival or FKBP5 expression were subjected to functional genomic study. Electromobility shift assay showed that the rs73748206 "A(T)" SNP altered DNA-protein binding patterns, consistent with significantly increased reporter gene activity, possibly through its increased binding to Glucocorticoid Receptor (GR). The effect of rs73748206 was confirmed on the basis of its association with FKBP5 expression by affecting the binding to GR in lymphoblastoid cell lines derived from the same patients for whom DNA was used for resequencing. CONCLUSION: This comprehensive FKBP5 resequencing study provides insights into the role of genetic variation in variation of gemcitabine response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Distant metastasis occurs late during the genetic evolution of pancreatic cancer
Yachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., Kamiyama, M., Hruban, R. H., Eshleman, J. R., Nowak, M. A., et al. (2010) · Nature · doi:10.1038/nature09515 · Cited by 2,502
Li, B., & Leal, S. M. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2008.06.024 · Cited by 1,527 · cited 1×
“To test the association between survival and SNPs, we used a rare variant burden type test [16].”
MethodBinder, E. B. (2009) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2009.05.021 · Cited by 968 · cited 12×
“Additionally, we performed gemcitabine cytotoxicity studies using cells overexpressing WT and variant constructs to see if these FKBP51 variant allozymes would affect response to drug treatment (Figure S1A).”
BackgroundInfluentialCellular pharmacology of gemcitabine
Mini, E., Nobili, S., Caciagli, B., Landini, I., & Mazzei, T. (2006) · Annals of Oncology · doi:10.1093/annonc/mdj941 · Cited by 842 · cited 2×
“Previous pharmacogenetic studies have focused on genes in the gemcitabine metabolism pathways and demonstrated that either expression or single nucleotide polymorphisms (SNPs) present in those genes could only explain a portion of the observed variability in drug response [5,6,7].”
BackgroundFKBP51 Affects Cancer Cell Response to Chemotherapy by Negatively Regulating Akt
Pei, H., Li, L., Fridley, B. L., Jenkins, G. D., Kalari, K. R., Lingle, W., Petersen, G., Lou, Z., & Wang, L. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.07.016 · Cited by 709
Self-citationThe glucocorticoid responses are shaped by molecular chaperones
Grad, I., & Picard, D. (2007) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2007.05.018 · Cited by 423 · cited 1×
“This relationship might be due to the fact that FKBP5 regulates GR activity [21,30,31] which influences GR function as a transcription factor that can regulate both FKBP5 gene expression and the expression of GR itself [26,27,28].”
BackgroundVermeer, H., Hendriks-Stegeman, B. I., van der Burg, B., van Buul-Offers, S. C., & Jansen, M. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020354 · Cited by 285 · cited 1×
“This relationship might be due to the fact that FKBP5 regulates GR activity [21,30,31] which influences GR function as a transcription factor that can regulate both FKBP5 gene expression and the expression of GR itself [26,27,28].”
BackgroundIntronic hormone response elements mediate regulation of FKBP5 by progestins and glucocorticoids
Hubler, T. R., & Scammell, J. G. (2004) · Cell Stress & Chaperones · doi:10.1379/csc-32r.1 · Cited by 201
Cited by
Gene–Stress–Epigenetic regulation of FKBP5: clinical and translational implications
Zannas, A. S., Wiechmann, T., Gassen, N. C., & Binder, E. B. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2015.235 · Cited by 622
“FKBP5 Genetic Variation With the use of tagging experiments and, more recently, next-generation sequencing, FKBP5 variants have been described in detail (Ellsworth et al, 2013a; Ellsworth et al, 2013b; Pelleymounter et al, 2011) (Figure 2).”
BackgroundMethodGene–environment interactions at the FKBP5 locus: sensitive periods, mechanisms and pleiotropism
Zannas, A. S., & Binder, E. B. (2014) · Genes, Brain and Behavior · doi:10.1111/gbb.12104 · Cited by 268
Wang, Q., Shelton, R. C., & Dwivedi, Y. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.08.066 · Cited by 201
In Vitro Human Cell Line Models to Predict Clinical Response to Anticancer Drugs
Niu, N., & Wang, L. (2015) · Pharmacogenomics · doi:10.2217/pgs.14.170 · Cited by 162
Self-citation
Metadata
- Authors
- Ellsworth, K. A., Eckloff, B. W., Li, L., Moon, I., Fridley, B. L., Jenkins, G. D., Carlson, E., Brisbin, A., Abo, R., Bamlet, W., Petersen, G., Wieben, E. D., & Wang, L.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-08-01
- Volume
- 8
- Issue
- 8
- Pages
- e70216
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W1983887038
- Cited by
- 48
- References
- 8
- FWCI
- 1.26
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Contribution of FKBP5 Genetic Variation to Gemcitabine Treatment and Survival in Pancreatic Adenocarcinoma. https://app.cochat.ai/papers/10.1371/journal.pone.0070216
- The paper
- Ellsworth, K. A., Eckloff, B. W., Li, L., Moon, I., Fridley, B. L., Jenkins, G. D., Carlson, E., Brisbin, A., Abo, R., Bamlet, W., Petersen, G., Wieben, E. D., & Wang, L. (2013). Contribution of FKBP5 Genetic Variation to Gemcitabine Treatment and Survival in Pancreatic Adenocarcinoma. PLoS ONE. https://doi.org/10.1371/journal.pone.0070216
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.